Trial Profile
Randomized crossover multi-facility joint comparative test to evaluate the effect on type 1 diabetic patient's blood glucose fluctuation due to difference in long-acting insulin (Insulin Degludec vs Insulin Glargine U300)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 26 Oct 2021 Status changed from recruiting to completed.
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2017 New trial record